<template>
    <div :class="[$style.section, 'black']">
        <div :class="$style.title">
            Источники
        </div>
        <div :class="$style.sources">
            <p>1. Ежов М.В., Кухарчук В.В., Сергиенко И.В., Алиева А.С., Анциферов М.Б., Аншелес А.А., Арабидзе Г.Г., Аронов Д.М., Арутюнов Г.П., Ахмеджанов Н.М., Балахонова Т.В., Барбараш О.Л., Бойцов С.А., Бубнова М.Г., Воевода М.И., Галстян Г.Р., Галявич А.С., Горнякова Н.Б., Гуревич В.С., Дедов И.И., Драпкина О.М., Дупляков Д.В., Ерегин С.Я., Ершова А.И., Иртюга О.Б., Карпов С.Р., Карпов Ю.А., Качковский М.А., Кобалава Ж.Д., Козиолова Н.А., Коновалов Г.А., Константинов В.О., Космачева Е.Д., Котовская Ю.В., Мартынов А.И., Мешков А.Н., Небиеридзе Д.В., Недогода С.В., Обрезан А.Г., Олейников В.Э., Покровский С.Н., Рагино Ю.И., Ротарь О.П., Скибицкий В.В., Смоленская О.Г., Соколов А.А., Сумароков А.Б., Филиппов А.Е., Халимов Ю.Ш., Чазова И.Е., Шапошник И.И., Шестакова М.В., Якушин С.С., Шляхто Е.В. Нарушения липидного обмена. Клинические рекомендации 2023.&nbsp;&nbsp;Российский кардиологический журнал. 2023;28(5):5471.&nbsp;&nbsp;https://doi.org/10.15829/1560-4071-2023-5471</p>
            <p>2. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011 May 19;473(7347):317-25. doi: 10.1038/nature10146. PMID: 21593864.</p>
            <p>3. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10;392(10159):1736-1788. doi: 10.1016/S0140-6736(18)32203-7. Epub 2018 Nov 8</p>
            <p>4. Российский статистический ежегодник. 2021: Стат.сб./Росстат. - М., 2021 - 692 c</p>
            <p>5. Tuzcu EM, Kapadia SR, Tutar E, Ziada KM, Hobbs RE, McCarthy PM, Young JB, Nissen SE. High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound. Circulation. 2001 Jun 5;103(22):2705-10. doi: 10.1161/01.cir.103.22.2705. PMID: 11390341.</p>
            <p>6. McGill HC Jr, McMahan CA, Zieske AW, Tracy RE, Malcom GT, Herderick EE, Strong JP. Association of Coronary Heart Disease Risk Factors with microscopic qualities of coronary atherosclerosis in youth. Circulation. 2000 Jul 25;102(4):374-9. doi: 10.1161/01.cir.102.4.374. PMID: 10908207.</p>
            <p>7. Atherosclerosis. Atherosclerosis and cholesterol. American Heart Association. Heart.org Web site. https://www.heart.org/en/health-topics/cholesterol/about-cholesterol/atherosclerosis. Updated November 6, 2020.&nbsp;</p>
            <p>8. Drapkina O.M., Imaeva A.E., Kutsenko V.A., Kapustina A.V., Balanova Yu.A., Maksimov S.A., Muromtseva G.A., Kotova M.B., Karamnova N.S., Evstifeeva S.E., Litinskaya O.A., Pokrovskaya M.S., Imaeva N.A., Filichkina E.M., Ivlev O.E., Svinin G.E., Gomanova L.I., Doludin Yu.V., Efimova I.A., Borisova A.L., Nazarov B.M., Yarovaya E.B., Repkina T.V., Gonoshilova T.O., Kudryavtsev A.V., Belova N.I., Shagrov L.L., Samotrueva M.A., Yasenyavskaya A.L., Chernysheva E.N., Glukhovskaya S.V., Levina I.A., Shirshova E.A., Dorzhieva E.B., Urbanova E.Z., Borovkova N.Yu., Kurashin V.K., Tokareva A.S., Ragino Yu.I., Simonova G.I., Shramko V.S., Nikulin V.N., Aslyamov O.R., Khokhlova G.V., Solovyova A.V., Rodionov A.A., Kryachkova O.V., Shamurova Yu.Yu., Tantsyreva I.V., Baryshnikova I.N., Ataev M.G., Radjabov M.O., Isakhanova M.M., Umetov M.A., Elgarova L.V., Khakuasheva I.A., Yamashkina E.I., Esina M.V., Kunyaeva T.A., Nikitina A.M., Savvina N.V., Spiridonova Yu.E., Naumova E.A., Keskinov A.A., Yudin V.S., Yudin S.M., Kontsevaya A.V., Shalnova S.A. Dyslipidemia in the Russian Federation: population data, associations with risk factors.&nbsp;&nbsp;Cardiovascular Therapy and Prevention. 2023;22(8S):3791. (In Russ.)&nbsp;https://doi.org/10.15829/1728-8800-2023-3791. EDN:&nbsp;DGYJLA</p>
            <template v-if="isShow">
                <p>9. Приказ Министерства здравоохранения РФ от 31 марта 2021 г. N 278 "Об утверждении методик расчета основных и дополнительных показателей федерального проекта "Борьба с сердечно-сосудистыми заболеваниями"</p>
                <p>10. Вторичные гиперлипидемии: этиология и патогенез. Ершова А. И.1, Аль Раши Д. О.2, Иванова А. А.2, Аксенова Ю. О.2, Мешков А. Н.1 Российский кардиологический журнал. 2019;24 (5):74–81 http://dx.doi.org/10.15829/1560-4071-2019-5-74-81</p>
                <p>11. Ежов Марат Владиславович – ORCID 0000 –0002–1518 –6552; Сергиенко Игорь Владимирович – ORCID 0000 –0003–1534–3965, Кухарчук Валерий Владимирович – ORCID 0000–0002 –7028 –362X. Атеросклероз и дислипидемии. Клинические рекомендации по нарушениям липидного обмена 2023. Что нового? 2023;3(52):5–9. DOI: 10.34687/2219 –8202.JAD.2023.03.0001</p>
                <p>12. Nair PA, Singhal R. Xanthelasma palpebrarum - a brief review. Clin Cosmet Investig Dermatol. 2017;11:1-5. Published 2017 Dec 18. doi:10.2147/CCID.S130116.</p>
                <p>13. Гордиенко А.В. Госпитальная терапия. – Издание: СпецЛит, 2014, 463 с.</p>
                <p>14. Ежов М.В., Бажан С.С., Ершова А.И., Мешков А.Н., Соколов А.А., Кухарчук В.В., Гуревич В.С., Воевода М.И., Сергиенко И.В., Шахтшнейдер Е.В., Покровский С.Н., Коновалов Г.А., Леонтьева И.В., Константинов В.О., Щербакова М.Ю., Захарова И.Н., Балахонова Т.В., Филиппов А.Е., Ахмеджанов Н.М., Александрова О.Ю., Липовецкий Б.М. КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ ПО СЕМЕЙНОЙ ГИПЕРХОЛЕСТЕРИНЕМИИ.&nbsp;Атеросклероз. 2019;15(1):58-98.</p>
                <p>15. РЕКОМЕНДАЦИИ ЕОК/ЕОСХ ПО ДИАГНОСТИКЕ И&nbsp;ЛЕЧЕНИЮ ЗАБОЛЕВАНИЙ ПЕРИФЕРИЧЕСКИХ АРТЕРИЙ 2017. Российский кардиологический журнал. 2018;23(8):164–221 http://dx.doi.org/10.15829/1560-4071-2018-8-164-221</p>
                <p>16. Клинические рекомендации Министерства здравоохранения Российской Федерации: Артериальная гипертензия у взрослых. 2020 г.</p>
                <p>17. SCORE2 working group and ESC Cardiovascular risk collaboration , SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe,&nbsp;European Heart Journal, Volume 42, Issue 25, 1 July 2021, Pages 2439–2454,&nbsp;https://doi.org/10.1093/eurheartj/ehab309</p>
                <p>18. 2021 Рекомендации ESC по профилактике сердечно-сосудистых заболеваний в клинической практике.&nbsp;Российский кардиологический журнал. 2022;27(7):5155.&nbsp;https://doi.org/10.15829/1560-4071-2022-5155</p>
                <p>19. Wiegman A., Gidding S.S., Watts G.F., et al.; European Atherosclerosis Society Consensus Panel. Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J. 2015;36(36):2425-2437. DOI: 10.1093/eurheartj/ ehv157</p>
                <p>20. Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Desvarieux M, . Ebrahim S, Fatar M, Hernandez Hernandez R, Kownator S, Prati P, Rundek T, . Taylor A, Bornstein N, Csiba L, Vicaut E, Woo KS, Zannad F, Advisory Board . of the 3rd Watching the Risk Symposium 2004, 13th European Stroke . Conference. Mannheim intima-media thickness consensus. Cerebrovasc Dis . 2004;18:346–349. .</p>
                <p>21. Inaba Y, Chen JA, Bergmann SR. Carotid plaque, compared with carotid intima- . media thickness, more accurately predicts coronary artery disease events: a . meta-analysis. Atherosclerosis 2012;220:128–133.</p>
                <p>22. Polak JF, Pencina MJ, Pencina KM, O’Donnell CJ, Wolf PA, D’Agostino RB Sr. . Carotid-wall intima-media thickness and cardiovascular events. N Engl J Med . 2011;365:213–221. .</p>
                <p>23. Колмакова Т.Е., Алексеева И.А., Тмоян Н.А., Ежов М.В. Эффективность высокоинтенсивной терапии розувастатином для вторичной профилактики сердечно-сосудистых осложнений у пациентов очень высокого риска. Атеротромбоз. 2021;11(2):56–75. https://doi.org/10.21518/2307-1109-2021-11-2-56-75.</p>
                <p>24. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal (2020) 41, 111􏰀188 doi:10.1093/eurheartj/ehz455</p>
                <p>25. Обрезан А.Г., Ежов М.В., Cергиенко И.В., Алиева А.С., Гуревич В.С. Место фиксированной комбинации розувастатина и фенофибрата в лечении пациентов с комбинированной атерогенной дислипидемией. Атеросклероз и дислипидемии. 2022;1(46):5–16. DOI: 10.34687/2219-8202.JAD.2022.01.0001</p>
                <p>26. Bershtein LL. New Possibilities to Reduce the Residual Risk in Patients With Ischemic Heart Disease. Kardiologiia. 2020;60(11):110-116. doi.org/10.18087/cardio.2020.11.n1370</p>
                <p>27. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther. 2006;112(1):71-105. doi: 10.1016/j.pharmthera.2006.03.003</p>
                <p>28. Martin PD, Dane AL, Nwose OM, Schneck DW, Warwick MJ. No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor. J Clin Pharmacol. 2002;42(10):1116-1121. doi: 10.1177/009127002401382722.</p>
                <p>29. Hu M, Tomlinson B. Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin. Expert Opin Drug Metab Toxicol. 2014;10(1):51-65. doi: 10.1517/17425255.2014.851667.</p>
                <p>30. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al.; STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003;92(2):152-160. doi: 10.1016/s0002-9149(03)00530-7</p>
                <p>31. Laks T, Keba E, Leiner M, Merilind E, Petersen M, Reinmets S, Väli S, Sööt T, Otter K. Achieving lipid goals with rosuvastatin compared with simvastatin in high risk patients in real clinical practice: a randomized, open-label, parallel-group, multi-center study: the DISCOVERY-Beta study. Vasc Health Risk Manag. 2008;4(6):1407-16. doi: 10.2147/vhrm.s4151. PMID: 19337553; PMCID: PMC2663459.</p>
                <p>32. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ et al.; JUPITER Trial Study Group. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373(9670):1175-1182. doi: 10.1016/S0140-6736(09)60447-5.</p>
                <p>33. Lind L, Peters SA, den Ruijter HM, Palmer MK, Grobbee DE, Crouse JR 3rd, O'Leary DH, Evans GW, RaichlenJS, Bots ML; METEOR Study Group. Effect of rosuvastatin on the echolucency of the common carotid intima-media in low-risk individuals: the METEOR trial. J Am Soc Echocardiogr. 2012;25(10):1120–1127.e1. doi: 10.1016/j.echo.2012.07.004.PMID: 22884641.</p>
                <p>34. Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, Libby P, Raichlen JS, Uno K, Borgman M, WolskiK, Nissen SE. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365(22):2078–87. doi: 10.1056/NEJMoa1110874. PMID: 22085316</p>
                <p>35. Общая характеристика лекарственного препарата Крестор (таблетки, покрытые оболочкой, 10, 20, 40 мг). Регистрационное удостоверение ЛП-N=(003184)-(PГ-RU) от 14.09.2023. https://astrazeneca.ru/astrazeneca_in_russia/preparations.html (Дата доступа &nbsp;16.07.2024)</p>
                <p>36. Olsson AG, McTaggart F, Raza A. Rosuvastatin – A highly effective new HMG-Co A reductase inhibitor. Cardiovasc Drug Rev. 2002;20(4):303-28.</p>
                <p>37. Leiter LA, Rosenson RS, Stein E, Reckless JP, Schulte KL, Schleman M, Miller P, Palmer M, Sosef F; POLARIS study investigators. Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study. Atherosclerosis. 2007 Oct;194(2):e154-64. doi: 10.1016/j.atherosclerosis.2006.12.001. Epub 2007 Jan 16. PMID: 17229426.</p>
                <p>38. Pitt B, Loscalzo J, Monyak J, Miller E, Raichlen J. Comparison of lipid-modifying efficacy of rosuvastatin versus atorvastatin in patients with acute coronary syndrome (from the LUNAR study). Am J Cardiol. 2012 May 1;109(9):1239-46. doi: 10.1016/j.amjcard.2011.12.015. Epub 2012 Feb 21. PMID: 22360820.</p>
                <p>39. Stalenhoef AF, Ballantyne CM, Sarti C, Murin J, Tonstad S, Rose H, Wilpshaar W. A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study. Eur Heart J. 2005 Dec;26(24):2664-72. doi: 10.1093/eurheartj/ehi482. Epub 2005 Sep 5. PMID: 16143705.</p>
                <p>40. Clearfield MB, Amerena J, Bassand JP, Hernández García HR, Miller SS, Sosef FF, Palmer MK, Bryzinski BS. Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia--Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR). Trials. 2006 Dec 21;7:35. doi: 10.1186/1745-6215-7-35. PMID: 17184550; PMCID: PMC1779361.</p>
                <p>41. Jukema JW, Liem AH, Dunselman PH, et al. LDL/HDL-C ratio in patients with cardiovascular disease and low HDL-C: results of the RADAR (Rosuvastatin and Atorvastatin in different Dosages And Reverse cholesterol transport) study. Curr Med Res Opin. 2005;21(11):1865-74.</p>
                <p>42. Wolffenbuttel BH, Franken AA, Vincent HH, et al. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes – CORALL study. J Int Med. 2005;257(6):531-9.</p>
                <p>43. Lloret R, Ycas J, Stein M, Haffner S; STARSHIP Study Group. Comparison of rosuvastatin versus atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial). Am J Cardiol. 2006 Sep 15;98(6):768-73. doi: 10.1016/j.amjcard.2006.04.014. Epub 2006 Jul 28. PMID: 16950182.</p>
                <p>44. Ferdinand KC, Clark LT, Watson KE, Neal RC, Brown CD, Kong BW, Barnes BO, Cox WR, Zieve FJ, Isaacsohn J, Ycas J, Sager PT, Gold A; ARIES Study Group. Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six-week trial. Am J Cardiol. 2006 Jan 15;97(2):229-35. doi: 10.1016/j.amjcard.2005.08.026. Epub 2005 Nov 28. PMID: 16442368.</p>
                <p>45. Deedwania PC, Gupta M, Stein M, Ycas J, Gold A; IRIS Study Group. Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial). Am J Cardiol. 2007 Jun 1;99(11):1538-43. doi: 10.1016/j.amjcard.2007.01.028. Epub 2007 Apr 16. PMID: 17531577.</p>
                <p>46. Insull W Jr, Ghali JK, Hassman DR, Y As JW, Gandhi SK, Miller E; SOLAR Study Group. Achieving low-density lipoprotein cholesterol goals in high-risk patients in managed care: comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trial. Mayo Clin Proc. 2007 May;82(5):543-50. doi: 10.4065/82.5.543. Erratum in: Mayo Clin Proc. 2007 Jul;82(7):890. PMID: 17493418.</p>
                <p>47. Schuster H, Barter PJ, Stender S, Cheung RC, Bonnet J, Morrell JM, Watkins C, Kallend D, Raza A; Effective Reductions in Cholesterol Using Rosuvastatin Therapy I study group. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. Am Heart J. 2004 Apr;147(4):705-13. doi: 10.1016/j.ahj.2003.10.004. PMID: 15077101.</p>
                <p>48. Ballantyne CM, Bertolami M, Hernandez Garcia HR, Nul D, Stein EA, Theroux P, Weiss R, Cain VA, Raichlen JS. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II. Am Heart J. 2006 May;151(5):975.e1-9. doi: 10.1016/j.ahj.2005.12.013. PMID: 16644314.</p>
                <p>49. Stalenhoef AF, Ballantyne CM, Sarti C, Murin J, Tonstad S, Rose H, Wilpshaar W. A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study. Eur Heart J. 2005 Dec;26(24):2664-72. doi: 10.1093/eurheartj/ehi482. Epub 2005 Sep 5. PMID: 16143705.</p>
                <p>50. Faergeman O, Hill L, Windler E, Wiklund O, Asmar R, Duffield E, Sosef F; ECLIPSE Study Investigators. Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study. Cardiology. 2008;111(4):219-28. doi: 10.1159/000127442. Epub 2008 Apr 23. PMID: 18434729.</p>
                <p>51. Betteridge DJ, Gibson JM. Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes. Diabet Med. 2007 May;24(5):541-9. doi: 10.1111/j.1464-5491.2007.02095.x. Epub 2007 Mar 15. PMID: 17367312.</p>
                <p>52. de Zeeuw D, Anzalone DA, Cain VA, et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. Lancet Diabetes Endocrinol. 2015;3(3):181-90.</p>
                <p>53. Sidaway JE, Davidson RG, McTaggart F, et al. Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells. J Am Soc Nephrol. 2004;15(9):2258-65.</p>
                <p>54. Willich SN, Englert H, Sonntag F, Völler H, Meyer-Sabellek W, Wegscheider K, Windler E, Katus H, Müller-Nordhorn J. Impact of a compliance program on cholesterol control: results of the randomized ORBITAL study in 8108 patients treated with rosuvastatin. Eur J Cardiovasc Prev Rehabil. 2009 Apr;16(2):180-7. doi: 10.1097/HJR.0b013e3283262ac3. PMID: 19174696.</p>
                <p>55. Nicholls SJ, Brandrup-Wognsen G, Palmer M, Barter PJ. Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol. 2010 Jan 1;105(1):69-76. doi: 10.1016/j.amjcard.2009.08.651. PMID: 20102893.</p>
                <p>56. Palmer MK, Nicholls SJ, Lundman P, Barter PJ, Karlson BW. Achievement of LDL-C goals depends on baseline LDL-C and choice and dose of statin: an analysis from the VOYAGER database. Eur J Prev Cardiol. 2013 Dec;20(6):1080-7. doi: 10.1177/2047487313489875. Epub 2013 May 3. PMID: 23644489.</p>
                <p>57. Karlson BW, Nicholls SJ, Lundman P, Barter PJ, Palmer MK. Modeling Statin-Induced Reductions of Cardiovascular Events in Primary Prevention: A VOYAGER Meta-Analysis. Cardiology. 2018;140(1):30–4. DOI: 10.1159/000488311</p>
                <p>58. Karlson BW, Barter PJ, Palmer MK, Lundman P, Nicholls SJ. Comparison of the effects of different statins and doses on lipid levels in patients with diabetes: Results from VOYAGER. Nutri- tion, Metabolism and Cardiovascular Diseases. 2012;22(9):697– 703. DOI: 10.1016/j.numecd.2012.03.003</p>
                <p>59. Karlson BW, Palmer MK, Nicholls SJ, Lundman P, Barter PJ. Doses of rosuvastatin, atorvastatin and simvastatin that induce equal reductions in LDL-C and non-HDL-C: Results from the VOYAGER meta-analysis. Eur J Prev Cardiol. 2016 May;23(7):744-7. doi: 10.1177/2047487315598710. Epub 2015 Aug 5. PMID: 26246463.</p>
                <p>60. Crouse JR 3rd, Raichlen JS, Riley WA, Evans GW, Palmer MK, O'Leary DH, Grobbee DE, Bots ML; METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA. 2007 Mar 28;297(12):1344-53. doi: 10.1001/jama.297.12.1344. Epub 2007 Mar 25. PMID: 17384434.</p>
                <p>61. Crouse JR 3rd, Grobbee DE, O'Leary DH, Bots ML, Evans GW, Palmer MK, Riley WA, Raichlen JS; Measuring Effects on intima media Thickness: an Evalution Of Rosuvastatin study group. Measuring Effects on intima media Thickness: an Evaluation Of Rosuvastatin in subclinical atherosclerosis--the rationale and methodology of the METEOR study. Cardiovasc Drugs Ther. 2004 May;18(3):231-8. doi: 10.1023/B:CARD.0000033645.55138.3d. PMID: 15229392.</p>
                <p>62. Fonarow GC. Randomized clinical outcome trials of statins in heart failure. Heart Fail Clin. 2008 Apr;4(2):225-9. doi: 10.1016/j.hfc.2008.02.001. PMID: 18433703.</p>
                <p>63. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM; ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006 Apr 5;295(13):1556-65. doi: 10.1001/jama.295.13.jpc60002. Epub 2006 Mar 13. PMID: 16533939.</p>
                <p>64. Underhill H.R., Yuan C., Zhao X.Q., et al. Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a highresolution magnetic resonance imaging trial. Am Heart J. 2008;155(3):584.e1-8. DOI: 10.1016/j.ahj.2007.11.018.</p>
                <p>65. Takayama T, Hiro T, Yamagishi M, Daida H, Hirayama A, Saito S, Yamaguchi T, Matsuzaki M; COSMOS Investigators. Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Circ J. 2009 Nov;73(11):2110-7. doi: 10.1253/circj.cj-09-0358. Epub 2009 Oct 5. PMID: 19801853.</p>
                <p>66. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008 Nov 20;359(21):2195-207. doi: 10.1056/NEJMoa0807646. Epub 2008 Nov 9. PMID: 18997196.</p>
                <p>67. McTaggart F. Comparative pharmacology of rosuvastatin. Atherosclerosis. 2003;Suppl4:9-14.</p>
                <p>68. Семенова А.Е., Сергиенко И.В. Розувастатин – статин с максимальным гиполипидемическим действием в профилактике сердечно-сосудистых осложнений. Евразийский кардиологический журнал. 2018, Май 25; 2:28-34</p>
                <p>69. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005;19:117-126.</p>
                <p>70. Strandberg TE, Feely J, Sigurdsson EL; DISCOVERY study group. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study. Clin Ther. 2004 Nov;26(11):1821-33. doi: 10.1016/j.clinthera.2004.11.015. PMID: 15639694.</p>
                <p>71. Keating A.J., Campbell K.B., Guyton J.R. Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy. Ann Pharmacother. 2013;47:398-404.</p>
                <p>72. Brewer HB Jr. Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams. Am J Cardiol. 2003 Aug 21;92(4B):23K-29K. doi: 10.1016/s0002-9149(03)00779-3. PMID: 12948873.</p>
                <p>73. Vidt DG, Cressman MD, Harris S, Pears JS, Hutchinson HG. Rosuvastatin-induced arrest in progression of renal disease. Cardiology. 2004;102(1):52-60. doi: 10.1159/000077704. Epub 2004 Apr 2. PMID: 15073451.</p>
                <p>74. Shepherd J, Vidt DG, Miller E, Harris S, Blasetto J. Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program. Cardiology. 2007;107(4):433-43. doi: 10.1159/000100908. Epub 2007 Mar 16. PMID: 17363845.</p>
                <p>75. Stein EA, Marais AD, Ducobu J, et al. Clin Lipidol 2007;1:287-99</p>
                <p>76. Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L, Pais P, López-Jaramillo P, Leiter LA, Dans A, Avezum A, Piegas LS, Parkhomenko A, Keltai K, Keltai M, Sliwa K, Peters RJ, Held C, Chazova I, Yusoff K, Lewis BS, Jansky P, Khunti K, Toff WD, Reid CM, Varigos J, Sanchez-Vallejo G, McKelvie R, Pogue J, Jung H, Gao P, Diaz R, Lonn E; HOPE-3 Investigators. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med. 2016 May 26;374(21):2021-31. doi: 10.1056/NEJMoa1600176. Epub 2016 Apr 2. PMID: 27040132.</p>
                <p>77. Sorof J. et al. Diabetes Research and Clinical Practise 2006; 72: 81-87</p>
                <p>78. Ridker PM, MacFadyen J, Cressman M, Glynn RJ. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. J Am Coll Cardiol. 2010;55(12):1266-73.</p>
                <p>79. Российское [АЕ1] кардиологическое общество (РКО) Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4083. https://doi.org/10.15829/1560-4071-2020-4083</p>
                <p>80. Verhulst A, D'Haese PC, De Broe ME. Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells. J Am Soc Nephrol. 2004;15(9):2249-57</p>
                <p>81. Simes J, Furberg CD, Braunwald E, Davis BR, Ford I, Tonkin A, Shepherd J. Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project. Eur Heart J. 2002 Feb;23(3):207-15. doi: 10.1053/euhj.2001.2775. PMID: 11792135.</p>
                <p>82. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003 Apr 5;361(9364):1149-58. doi: 10.1016/S0140-6736(03)12948-0. PMID: 12686036.</p>
            </template>
        </div>
        <ButtonAction
            v-show="!isShow"
            :class="$style.button"
            title="Все источники"
            preset="black"
            @handleClick="showSources"
        />
    </div>
</template>

<script>
import ButtonAction from '~/components/common/ButtonAction/index.vue'

export default {
    name: 'SectionTwentyOne',
    components: {
        ButtonAction
    },
    data: function () {
        return {
            isShow: false
        }
    },
    methods: {
        showSources () {
            this.isShow = true
        }
    }
}
</script>

<style module lang="scss">
    .section {
        @include wrapper;

        position: relative;
        padding-top: rem(120);
        padding-bottom: rem(120);

        @include mobile {
            padding-top: rem(90);
            padding-bottom: rem(90);
        }
    }

    .title {
        @include block-title;
    }

    .sources {
        margin-top: rem(30);
        font-size: rem(15);

        @include mobile {
            margin-top: rem(20);
            font-size: rem(14);
        }

        p {
            @include mobile {
                word-break: break-all;
            }
        }

        p + p {
            margin-top: rem(10);
        }
    }

    .button {
        margin-top: rem(40);

        @include mobile {
            margin-top: rem(40);
        }
    }
</style>
